Loading
A phase 3 trial of Camrelizumab, Rivoceranib in hepatocellular carcinoma, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma is a phase 3 interventional study registered as NCT05320692 by Jiangsu HengRui Medicine Co., Ltd., with 423 participants enrolled, started 2022-08-09 and due to reach its primary completion in 2026-07-30. Interventions recorded: TACE+Camrelizumab+Apatinib mesylate, TACE. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy.
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Rivoceranib (apatinib), Camrelizumab, Jiangsu Hengrui Pharmaceuticals.
Shares Intermediate hepatocellular carcinoma (BCLC B), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.
Shares Rivoceranib (apatinib), Jiangsu Hengrui Pharmaceuticals, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals, Immune checkpoint inhibitors.
Shares Rivoceranib (apatinib), Camrelizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/